tiprankstipranks
TipRanksStock Market NewsPFE NewsAnalysts Offer Insights on Healthcare Companies: Pfizer (PFE), Apollo Endosurgery (APEN) and Biogen (BIIB)
Blurbs

Analysts Offer Insights on Healthcare Companies: Pfizer (PFE), Apollo Endosurgery (APEN) and Biogen (BIIB)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Pfizer (PFEResearch Report), Apollo Endosurgery (APENResearch Report) and Biogen (BIIBResearch Report).

Pfizer (PFE)

Morgan Stanley analyst Terence Flynn maintained a Hold rating on Pfizer today and set a price target of $52.00. The company’s shares closed last Wednesday at $49.07.

According to TipRanks.com, Flynn is a 4-star analyst with an average return of 13.6% and a 64.8% success rate. Flynn covers the Healthcare sector, focusing on stocks such as Arvinas Holding Company, Johnson & Johnson, and Merck & Company.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Pfizer with a $58.92 average price target, a 20.5% upside from current levels. In a report issued on April 21, Berenberg Bank also maintained a Hold rating on the stock with a $50.00 price target.

See the top stocks recommended by analysts >>

Apollo Endosurgery (APEN)

In a report released today, Chris Cooley from Stephens maintained a Buy rating on Apollo Endosurgery, with a price target of $9.00. The company’s shares closed last Wednesday at $5.34, close to its 52-week low of $4.52.

According to TipRanks.com, Cooley is a 5-star analyst with an average return of 22.3% and a 60.1% success rate. Cooley covers the Healthcare sector, focusing on stocks such as Anika Therapeutics, Pulse Biosciences, and SmileDirectClub.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Apollo Endosurgery with a $10.33 average price target, implying a 101.0% upside from current levels. In a report released today, Stifel Nicolaus also reiterated a Buy rating on the stock with a $10.00 price target.

Biogen (BIIB)

Morgan Stanley analyst Matthew Harrison maintained a Buy rating on Biogen today and set a price target of $285.00. The company’s shares closed last Wednesday at $206.20, close to its 52-week low of $192.67.

According to TipRanks.com, Harrison is a 5-star analyst with an average return of 8.9% and a 52.1% success rate. Harrison covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Centessa Pharmaceuticals, and BioMarin Pharmaceutical.

Currently, the analyst consensus on Biogen is a Moderate Buy with an average price target of $242.14, which is a 16.2% upside from current levels. In a report issued on April 21, SVB Securities also maintained a Buy rating on the stock with a $270.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on PFE:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More